Amicus Therapeutics is an American biopharmaceutical company located in Cranbury, New Jersey. In 2007 the company went public after a planned offering in 2006 followed by a withdrawal. The offering would have made AMTX the established symbol for trading. Amicus was funded by numerous capital firms including New Enterprise Associates, Radius Ventures and Canaan Partners.
Amicus Therapeutics focuses on rare and orphan diseases although their main objective is a disorder called lysosomal storage. The development of the company’s products is based on the Chaperone-Advanced Replacement Therapy also referred to as CHART. They have concentrated on developing therapies for enzyme replacement. Amicus’s reputation expanded in 2004 when their broadcast portfolio was noted in the pharmaceutical industry for small molecule pharmacological chaperones.
Amicus Therapeutics had no products marketed in 2014 and their most likely candidate was migalastat which uses the trade name of Galafold. The product is a treatment for Fabry disease with the goal of stabilizing endogenous mutant alpha-galactosidase. The company is also involved with JCR Pharmaceutical and GlaxoSmithKline in the investigation of coformulation with recombinant alpha-galactosidase. This partnership began in 2010 and continued until 2013.
Amicus Therapeutics expanded from their only site in New Jersey in 2008 to an additional research facility located in San Diego, California. By the end of 2009 the termination of a long collaboration with Shire caused financial setbacks. At this point in time private placements were used to finance their operations. This occurred with the use of proceeds secured with their first public offering, preferred stock and the agreement they had with Shire. The began restructuring at a corporate level to reduce their workforce by twenty percent.
Amicus Therapeutics received a United States grant in 2010. The $500,000 was received from the Michael J. Fox Foundation to support collaborative studies at UCLA with the David Geffen School of Medicine. An additional $210,300 grant was received in 2010 from the foundation for Alzheimer Drug Discovery. The grant supported their pre-clinical work and was a collaboration between Amicus and Mount Sinai’s Icahn School of Medicine. Amicus acquired the company Scioderm in September of 2015 for $947 million in stocks and cash.
More about Amicus Therapeutics here : Facebook | Crunchbase | Twitter
In a bid to provide better health care services and models to individuals, ID Life recently announced its partnership with one of the world’s best brand in wearable modern technology, Garmin International. The partnership was based on providing state of the art tracking devices that can help with monitoring and evaluate a customer’s health as well as wellness journey. The Garmin IndexTM is a machine that provides metrics based on the health of an individual. ID Life is prominent for providing nutritional products and vitamins for better health.
Recently, most clients across the world gave positive feedback on the lasting healthy experiences achieved from the products produced by IDLife. The program which is dubbed IDLife Experience is a health and wellness initiative that is designed to assist individuals with investing in healthy life routines. The initiative to merge with Garmin wellness was a mark of success for IDLife.
Garmin is a multinational technology company specializing in producing wearable devices tailored to the specifications of a client. In addition to the index of scale that the firm is partnering with IDLife Wellness, the two firms have an application that focuses on applying Garmin’s vivo trackers based on tracking a person’s physical activities. The vivo line provides a long battery life that would serve a client up to approximately one year. The other enticing feature in the partnership is the wristband device that monitors an individual’s heart rate. The device features smart notifications that can track an individual’s workout rates. This device comes in different colors, sizes as well as styles.
Logan is an executive entrepreneur and former athlete. He is also best-selling author, philanthropist, and leadership trainer. Throughout his career, Logan generated billions of dollars. His track record of leadership speaks volumes of achievement in team building, entrepreneurship, success principles speaker as well as a leadership trainer. Through the same leadership skills, Logan Stout has managed to build several businesses with the primary success of the ventures being ID Life, a wellness program initiated to provide individuals with vitamins as well as routines that promote health. The alumnus of Panola College studied business to hone his skills in entrepreneurship. He also attended the Dallas University for a degree in psychology.